Celularity Secures $12.2 Million from Sale of Tax Credits and NOLs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy CELU?
Source: Newsfilter
- Capital Injection: Celularity secured $12.2 million in net cash proceeds from the sale of approximately $126.3 million in unused New Jersey net operating losses (NOLs) and $1.9 million in R&D tax credits, significantly enhancing the company's liquidity and financial stability.
- Non-Dilutive Capital: This funding is viewed as non-dilutive and tax-free capital that supports Celularity's capital allocation towards commercial opportunities in stem cell and regenerative medicine programs, particularly targeting longevity.
- Policy Support: The transaction was facilitated through New Jersey's Technology Business Tax Certificate Transfer Program, which aims to assist technology and life sciences companies in converting NOLs and R&D tax credits into cash, demonstrating state support for innovative enterprises.
- Future Outlook: The CEO of Celularity stated that this funding will aid the company's ongoing development in regenerative medicine, especially in developing therapeutic solutions addressing aging mechanisms and related diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELU
About CELU
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
Celularity Enters Strategic Partnership for Biomaterials
- Strategic Partnership: Celularity has entered into definitive agreements for a strategic commercialization partnership that could yield up to $35 million in upfront and milestone payments, significantly enhancing the company's liquidity and market competitiveness.
- Exclusive Licensing: The company granted an exclusive license for its commercial-stage biomaterials portfolio and certain development-stage programs, with the transaction expected to close by April 15, 2026, ensuring future market expansion potential.
- Manufacturing Rights Retained: Celularity will retain exclusive manufacturing rights for the licensed products at its Florham Park, New Jersey facility and will be eligible for royalties on future net sales of certain development-stage products upon commercialization, further strengthening its revenue streams.
- Organizational Realignment: The company plans an organizational realignment, including workforce reductions and the transition of certain personnel to the commercial partner, aimed at lowering operating expenses and improving capital efficiency to better focus resources on advancing its longevity-focused therapeutic pipeline.
See More
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
See More
NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026
Funding Expectations: NEXGEL anticipates closing an additional financing round of $14.9 million in the first quarter or early second quarter of 2026.
Financial Strategy: The company is actively seeking to secure funds to support its growth and operational needs.
See More
NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing
- Revenue Expectations: Nexgelin's deal is anticipated to triple its annual revenue to $35 million.
- Profitability Outlook: The company is expected to become profitable upon closing the deal.
See More
NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration
- Financial Details: The deal includes a $15 million upfront cash payment.
- Potential Earnings: There is a possibility of up to $20 million in milestone payments.
See More
NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products
Announcement of Consideration: Nexgel has announced its consideration of terms for an agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products.
Focus on Regenerative Biomaterials: The agreement aims to enhance Nexgel's offerings in the field of regenerative biomaterials, which are used in various medical and commercial applications.
See More
Celularity Enters Strategic Partnership for Biomaterials
- Strategic Partnership: Celularity has entered into definitive agreements for a strategic commercialization partnership that could yield up to $35 million in upfront and milestone payments, significantly enhancing the company's liquidity and market competitiveness.
- Exclusive Licensing: The company granted an exclusive license for its commercial-stage biomaterials portfolio and certain development-stage programs, with the transaction expected to close by April 15, 2026, ensuring future market expansion potential.
- Manufacturing Rights Retained: Celularity will retain exclusive manufacturing rights for the licensed products at its Florham Park, New Jersey facility and will be eligible for royalties on future net sales of certain development-stage products upon commercialization, further strengthening its revenue streams.
- Organizational Realignment: The company plans an organizational realignment, including workforce reductions and the transition of certain personnel to the commercial partner, aimed at lowering operating expenses and improving capital efficiency to better focus resources on advancing its longevity-focused therapeutic pipeline.
See More
NexGel Expects Revenue to Triple
- Milestone Transaction: NexGel's recent transaction is regarded as a significant milestone in its history, with expected annual revenue reaching approximately $35 million by 2026, nearly tripling current figures, thus enabling immediate profitability and enhancing its position in the medical technology sector.
- Expanded Product Portfolio: The deal adds six commercially viable regenerative biomaterial products with proven clinical utility, which not only meet market demand but also have insurance reimbursement coverage, thereby supporting a stable revenue base.
- Future Growth Pipeline: NexGel plans to file three additional 510(k) applications in 2026, 2027, and 2028, providing a visible growth pipeline for its portfolio and further strengthening its competitive edge in the market.
- Financing and Strategic Investments: The company anticipates closing approximately $14.9 million in financing during the first or early second quarter of 2026, alongside a previously announced financing of about $1.8 million, indicating a proactive approach to acquisitions and enhancing its market expansion capabilities.
See More
NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026
Funding Expectations: NEXGEL anticipates closing an additional financing round of $14.9 million in the first quarter or early second quarter of 2026.
Financial Strategy: The company is actively seeking to secure funds to support its growth and operational needs.
See More
